Key result
The continuation or discontinuation of renin-angiotensin-aldosterone system blockers in the peri-operative period requires careful justification due to risks of hypotension and renal dysfunction.
Why the study?
Does the continuation or discontinuation of renin-angiotensin-aldosterone system blockers in the peri-operative period affect the risk of post-operative complications in patients undergoing surgery?
Population
Patients undergoing cardiac and non-cardiac surgery and suffering from cardiac vascular diseases
Design
Review
Authors
Loading...
Requires cautious individualized peri-operative RAAS blocker decisions to mitigate hypotension and renal risks; leaves open optimal strategies for prospective trials.
Does the continuation or discontinuation of renin-angiotensin-aldosterone system blockers in the peri-operative period affect the risk of post-operative complications in patients undergoing surgery?
This review highlights the clinical dilemma of managing RAAS blockers in the peri-operative period, balancing their long-term cardiovascular benefits against the acute risks of post-operative hypotension and renal dysfunction.
Ломиворотов et al. (2018) conducted a review in Cardiac vascular diseases undergoing surgery. Discontinuation of renin-angiotensin-aldosterone system blockers vs. Continuation was evaluated. The continuation or discontinuation of renin-angiotensin-aldosterone system blockers in the peri-operative period requires careful justification due to risks of hypotension and renal dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: